Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).
作者信息
Hirst C, Raasch S, Llewelyn G, Robertson N
出版信息
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):800-2. doi: 10.1136/jnnp.2005.076869.
Abstract
摘要
相似文献
1
Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).阿仑单抗（Campath 1H）治疗后慢性炎症性脱髓鞘性多发性神经病的缓解
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):800-2. doi: 10.1136/jnnp.2005.076869.
2
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.阿仑单抗治疗 IVIG 依赖性慢性炎症性脱髓鞘性多发性神经病。
J Neurol. 2010 Jun;257(6):913-9. doi: 10.1007/s00415-009-5437-3. Epub 2010 Jan 6.
3
Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.阿仑单抗（Campath-1H）用于治疗难治性多发性肌炎。
J Rheumatol. 2008 Oct;35(10):2080-2.
4
Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?阿仑单抗：慢性炎症性脱髓鞘性多发性神经根神经病治疗的未来？
Expert Rev Clin Immunol. 2010 May;6(3):319-21. doi: 10.1586/eci.10.23.
5
Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus.利妥昔单抗治疗与糖尿病相关的慢性炎症性脱髓鞘性多发性神经病
J Neurol Sci. 2007 May 15;256(1-2):100-2. doi: 10.1016/j.jns.2007.02.027. Epub 2007 Mar 23.
6
Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.抗CD52抗体CAMPATH 1-H导致淋巴细胞耗竭后白塞病的缓解诱导。
Rheumatology (Oxford). 2003 Dec;42(12):1539-44. doi: 10.1093/rheumatology/keg424. Epub 2003 Aug 29.
7
Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment.红斑狼疮性系统性多神经根炎伴慢性炎症性脱髓鞘性多发性神经病，利妥昔单抗治疗后预后良好。
Rheumatol Int. 2012 Dec;32(12):4061-3. doi: 10.1007/s00296-011-2130-5. Epub 2011 Sep 16.
8
Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.使用Campath-1H实现严重难治性自身免疫性中性粒细胞减少症的持续缓解。
Br J Haematol. 1997 May;97(2):306-8. doi: 10.1046/j.1365-2141.1997.612718.x.
9
Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.阿仑单抗（Campath 1H）作为复发性类固醇抵抗性心脏移植排斥反应的成功挽救疗法。
J Heart Lung Transplant. 2007 Jul;26(7):750-2. doi: 10.1016/j.healun.2007.04.012.
10
Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).使用淋巴细胞清除抗体阿仑单抗（CAMPATH-1H）治疗复发性/难治性抗中性粒细胞胞浆抗体相关性血管炎的长期随访
Ann Rheum Dis. 2008 Sep;67(9):1322-7. doi: 10.1136/ard.2007.081661. Epub 2007 Nov 29.
引用本文的文献
1
Progress in Hematopoietic Stem Cell Transplantation for CIDP.进展性神经病中的造血干细胞移植。
Int J Med Sci. 2020 Jan 14;17(2):234-241. doi: 10.7150/ijms.38363. eCollection 2020.
2
Immune-mediated neuropathies.免疫介导性神经病。
Nat Rev Dis Primers. 2018 Oct 11;4(1):31. doi: 10.1038/s41572-018-0027-2.
3
Novel pathomechanisms in inflammatory neuropathies.炎症性神经病的新发病机制。
J Neuroinflammation. 2017 Nov 28;14(1):232. doi: 10.1186/s12974-017-1001-8.
4
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.除皮质类固醇、免疫球蛋白和血浆置换外，用于慢性炎性脱髓鞘性多发性神经根神经病的免疫调节治疗
Cochrane Database Syst Rev. 2017 May 8;5(5):CD003280. doi: 10.1002/14651858.CD003280.pub5.
5
Autoimmune neuromuscular disorders.自身免疫性神经肌肉疾病。
Curr Neuropharmacol. 2011 Sep;9(3):400-8. doi: 10.2174/157015911796558000.
6
Pathogenesis and treatment of immune-mediated neuropathies.免疫介导性神经病变的发病机制与治疗。
Ther Adv Neurol Disord. 2009 Jul;2(4):261-81. doi: 10.1177/1756285609104792.
7
Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.儿童炎性脱髓鞘疾病的临床和药理学方面：最新进展。
Curr Neuropharmacol. 2010 Jun;8(2):135-48. doi: 10.2174/157015910791233141.
8
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.阿仑单抗治疗 IVIG 依赖性慢性炎症性脱髓鞘性多发性神经病。
J Neurol. 2010 Jun;257(6):913-9. doi: 10.1007/s00415-009-5437-3. Epub 2010 Jan 6.
9
Molecularly targeted therapies for dysimmune neuropathies.自身免疫性神经病的分子靶向治疗
Mol Med. 2009 Jul-Aug;15(7-8):283-7. doi: 10.2119/molmed.2009.00041. Epub 2009 May 5.
10
Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.慢性炎症性脱髓鞘性多发性神经根神经病的新型治疗选择。
Drugs. 2009 May 29;69(8):987-1001. doi: 10.2165/00003495-200969080-00004.
本文引用的文献
1
Rituximab-responsive CIDP.利妥昔单抗反应性慢性炎性脱髓鞘性多发性神经病
Eur J Neurol. 2004 Nov;11(11):788. doi: 10.1111/j.1468-1331.2004.00911.x.
2
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.基于阿仑单抗的减低强度异基因移植后的神经系统并发症。
Bone Marrow Transplant. 2004 Jul;34(2):137-42. doi: 10.1038/sj.bmt.1704538.
3
Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy.用于慢性炎症性脱髓鞘性多发性神经根神经病的细胞毒性药物和干扰素。
Cochrane Database Syst Rev. 2003(1):CD003280. doi: 10.1002/14651858.CD003280.
4
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.单克隆抗体治疗揭示了多发性硬化症临床病程背后的三种机制。
Ann Neurol. 1999 Sep;46(3):296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#.
5
Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases.格林-巴利综合征和慢性炎症性脱髓鞘性多发性神经病患者中HPRT突变T淋巴细胞频率增加：T细胞在周围性脱髓鞘疾病病因学中作用的进一步证据。
J Neuroimmunol. 1995 Apr;58(1):37-42. doi: 10.1016/0165-5728(94)00185-q.
6
Reshaping human antibodies for therapy.重塑用于治疗的人源抗体。
Nature. 1988 Mar 24;332(6162):323-7. doi: 10.1038/332323a0.
Zotero 插件